

KNOWLEDGE SHARING AND CAPACITY BUILDING

- Comparability is a risk assessment-driven exercise and the *foundation to justifying innovative study designs* with limited batches and data.
- Taking a platform-wide strategic view offers *new opportunities to leverage prior knowledge*.
- *mRNA therapeutics present unique aspects* for individualized products, LNP production, & characterization.
- PPQ is context-specific: *plan early and have good methods*.
- Genome/epigenome-editing products call for *multilayered control strategies and a readiness to move quickly* through clinical development.

CELL & GENE THERAPY PRODUCTS 2026
BY THE NUMBERS



Total
Attendees

352



First-Time
Attendees

168



Companies
Represented

107



Regulatory
Participation

54



Country Participation

15

Austria | Belgium | Canada | China | Denmark | France |
Germany | Ireland | Italy | Japan | Netherlands | Spain |
Sweden | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. www.casss.org